GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc notified the market that 19,352 ordinary shares of 31¼ pence each were admitted to trading under existing block listing admissions connected with its Share Save Plan 2022. The admission covered August 7, 2026, through October 2, 2026, on the London Stock Exchange Main Market. The total number of securities admitted to trading following admission was 4,316,311,662, and the shares are fully fungible with existing ordinary shares.
GSK plc reported that its issued share capital consisted of 4,316,311,549 Ordinary Shares as of September 30, 2026, including 270,881,064 shares held in Treasury. Total voting rights were 4,045,430,485, which shareholders may use as the denominator for determining whether they must notify the company of an interest or a change in an interest.
GSK plc reported that its President, Maya Martinez-Davis, acquired 9.414 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction was listed at a price of $50.7200 on September 22, 2026, with the New York Stock Exchange shown as the place of transaction.
GSK plc (GSK) reports that several persons discharging managerial responsibilities, including Non-Executive Chair Sir Jonathan Symonds and multiple Independent Non-Executive Directors, purchased GSK securities on September 18, 2026 on the London Stock Exchange and New York Stock Exchange.
Transactions included purchases of Ordinary Shares in London and American Depositary Shares in New York at disclosed per-share prices in single, on-market trades for each individual.
GSK plc (GSK) announced an agreement to acquire full global rights to a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. The programme is expected to enter phase I clinical trials in 2027, subject to customary closing conditions.
The TCE is designed to bind T cells while targeting two validated tumour-associated antigens, aiming for deeper and more durable responses and improved tolerability compared with existing TCEs. GSK states that this asset complements its existing multiple myeloma and broader blood cancer portfolio and builds on a prior agreement with Chimagen for a dual CD19/CD20 TCE.
Under the agreement, GSK will pay an upfront fee and may make additional success-based development and commercial milestone payments, for a total potential deal value of up to $750 million. GSK highlights external forecasts that the US TCE market for multiple myeloma could exceed $10 billion by 2032.
GSK plc (GSK) reported pivotal phase III data from the ARTEMIS-008 trial in China showing that B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) reduced the risk of death by 54% versus topotecan in relapsed small cell lung cancer after platinum-based therapy (HR 0.46; 95% CI: 0.35–0.62, p<0.0001).
Patients on Ris-Rez had median overall survival of 18.5 months compared with 10.3 months for topotecan, with consistent benefits across secondary endpoints: longer progression-free survival, higher objective response and disease control rates, and fewer grade ≥3 treatment-related adverse events. GSK holds exclusive rights outside Greater China and is running a broad global programme, including the phase III EMBOLD SCLC-301 trial with pivotal data expected next year.
GSK plc (GSK) reported positive registrational phase I/II ARROS-1 data for its ROS1 tyrosine kinase inhibitor Jideytro (zidesamtinib) in TKI‑naïve patients with advanced or metastatic ROS1‑positive non-small cell lung cancer. In 94 efficacy‑evaluable patients, Jideytro achieved a 94% objective response rate, including a 15% complete response rate, after a median follow‑up of 15.2 months. Responses appeared durable, with 94% of patients still responding at nine months and 86% at 12 months; 12‑month progression‑free survival was 90%, while median duration of response and median PFS were not yet reached.
All patients with measurable brain metastases (10/10) responded, and 70% achieved complete clearance of detectable brain tumours, with 78% maintaining intracranial response at 12 months. Treatment‑related adverse events were mostly low grade; dose reductions occurred in 11% of patients and discontinuations in 1%. GSK plans a supplemental New Drug Application in the US in 2026 to seek expansion of Jideytro’s indication to first-line ROS1‑positive NSCLC, adding to its July 2026 US approval in previously TKI‑treated patients.
GSK plc (GSK) reported that multiple senior managers and one person closely associated with a manager acquired Ordinary Shares of 31¼ pence each under the company’s Share Reward Plan. Each participant acquired 7 partnership shares and 7 matching shares, totaling 14 Ordinary Shares each at £18.0296 per share on September 9, 2026, on the London Stock Exchange.
GSK plc (GSK) reported a transaction by senior executive Maya Martinez-Davis, President, involving American Depositary Shares (ADS).
On September 8, 2026, Ms Martinez-Davis acquired 9.837 notional ADS within her GSK Executive Supplemental Savings Plan account at a price of $48.5400 per ADS on the New York Stock Exchange.
GSK plc (GSK) reports that Japan’s Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its Recombinant Zoster Vaccine, for the prevention of shingles. This new ready-to-use format replaces the prior two-vial presentation and is intended to simplify and make administration more convenient for healthcare professionals.
Shingrix has been approved in Japan to prevent herpes zoster in adults aged 50 and older since 2018, and in adults aged 18 and older at increased risk since 2023. GSK states that the prefilled syringe presentation is already available in the US and is launching in Europe in 2026, with the Japanese approval based on data showing technical comparability to the existing formulation and no change in indication or dosing.